Patents Examined by Shin-Lin Chen
  • Patent number: 10973852
    Abstract: NK cell based cancer immunotherapy, and particularly genetically modified NK92 cell-based immunotherapy is enhanced by expression CXCL12 and/or by suppression or deletion of CXCR4 in the natural killer cells to so reduce aggregation, rejection, and/or fratricide of the natural killer cells. Provided herein are genetically engineered NK (natural killer) cell comprising a recombinant nucleic acid encoding at least a portion of chemokine C—X—C motif ligand 12 (CXCL12), and a transcript for downregulation of chemokine C—X—C motif receptor 4 (CXCR4).
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: April 13, 2021
    Assignee: NantCell, Inc.
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
  • Patent number: 10973765
    Abstract: Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: April 13, 2021
    Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Yong Song Gho, Dong-Sic Choi, Gyeongyun Go
  • Patent number: 10959413
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 30, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Patent number: 10959412
    Abstract: A method for creating an animal model of traumatic optic nerve injury, including fully exposing an internal segment of an optic canal as well as adjacent anterior skull base, posterior ethmoid sinus and lateral sphenoid sinus walls through an ethmoid sinus-sphenoid sinus operation pathway under an endoscope, and impacting different sites of the internal segment of the optic canal with controllable impact force to cause optic nerve injury so as to prepare a controllable and quantifiable TONI bionic elastic injury animal model reflecting contusion to an internal segment of an optic canal in a human TONI clinical injury state. With less intracranial combined injury to the animal, the survival rate is high. Different sites of the optic canal are impacted with quantifiable elastic force for the quantitative and qualitative purposes with respect to the injured parts and the injury degree.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 30, 2021
    Assignee: The Eye Hospital of Wenzhou Medical University
    Inventors: Wencan Wu, Kaihui Nan, Ende Wu, Yuanyuan Chen, Jing Zhou
  • Patent number: 10945418
    Abstract: This disclosure relates to genetically modified animal expressing human or chimeric (e.g., humanized) programmed death-ligand 1 (PD-L1, PDL1, or B7-H1), and methods of use thereof. In one aspect, the disclosure relates to genetically-modified, non-human animals whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric programmed death-ligand 1 (PD-L1).
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 16, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Yanan Guo, Rui Huang, Xiaofei Zhou, Chaoshe Guo
  • Patent number: 10941452
    Abstract: A method useful for identifying and isolating live circulating tumor cells is described. The method utilizes an adenoviral vector comprising a replication-competent adenovirus in which the E1 gene region is expressed under the control of a telomerase-specific promoter and further comprises a second expression cassette containing a marker protein, optionally fused to a detectable cell surface marker to permit detection of circulating tumor cells lacking cell surface markers. The method involves combining ex vivo a test sample from a patient suspected of having circulating tumor cells, an adenoviral probe system, and culture media for the cells. The test sample is incubated with the adenoviral system for a sufficient time to permit expression of the reporter protein. The marker gene expression can thereafter be quantitated and the marker-expressing cells may optionally be collected for further analysis.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: March 9, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jay F. Dorsey, Gary D. Kao, Stephen M. Hahn
  • Patent number: 10925263
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: February 23, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Patent number: 10928383
    Abstract: A method for predicting an effect of a medication or a treatment regimen to a subject suffering from a cancer, the method comprises: (A) obtaining a tissue from the subject; (B) dissociating the tissue to obtain a multicellular cluster, wherein the multicellular cluster comprises the cancer cell; (C) culturing the multicellular cluster on a cellulose sponge; (D) exposing the cultured multicellular cluster to the medication or the treatment regimen; and (E) measuring a first survival rate of the cancer cell before exposing to the medication or the treatment regimen and a second survival rate of the cancer cell after exposing to the medication or the treatment regimen, when the second survival rate is lower than the first survival rate, the method predicts positive effect of the medication or the treatment regimen to the subject.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 23, 2021
    Assignee: SHANXI PISHON BIOMEDICAL TECHNOLOGY CO., LTD
    Inventors: Chih-Chiang Hsieh, Yen Chang
  • Patent number: 10920245
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 16, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Samuel Wadsworth
  • Patent number: 10918768
    Abstract: The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: February 16, 2021
    Assignee: Stratatech Corporation
    Inventors: John M. Centanni, B. Lynn Allen-Hoffman
  • Patent number: 10905777
    Abstract: The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 2, 2021
    Assignee: DNARx
    Inventors: Robert James Debs, Timothy D. Heath, Chakkrapong Handumrongkul
  • Patent number: 10888589
    Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Alan P. Wolffe, Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov
  • Patent number: 10889845
    Abstract: The present invention relates to a cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in improvement of pharmacokinetic properties, i.e. by attaching PEG chains to proteins. The present invention also relates to methods for producing the antibodies and compositions comprising the antibodies, and their uses.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: January 12, 2021
    Assignees: UNIVERSITY OF COPENHAGEN, DANMARKS TEKNISKE UNIVERSITET
    Inventors: Shamim Herbert Rahman, Carsten Behrens, Malene Bech Vester-Christensen, Henrik Clausen, Zhang Yang, Adnan Fevzi Halim, Eric Bennett
  • Patent number: 10865424
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: December 15, 2020
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Patent number: 10857187
    Abstract: Brain injury can be caused by trauma or may occur in stroke or neurodegenerative diseases. The disclosure relates to compositions that can include exosomes isolated from human adipose-derived stem cells (hASC) and methods where exosomes from hASC may be used alone or in combination with insulin for the treatment of brain injury.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 8, 2020
    Assignee: University of South Florida
    Inventors: Niketa A. Patel, Paula Cole Bickford
  • Patent number: 10849990
    Abstract: The present invention relates to a method for treating Parkinson's disease. According to this method, a halorhodopsin protein, a polynucleotide encoding the halorhodopsin protein or a vector containing the polynucleotide above is introduced into ventrolateral thalamus (VL) or medial globus pallidus (GPm) neurons of a subject having Parkinson's disease. The VL neurons are then illuminated with green light or exposed to a T type Ca2+ channel blocker to inhibit rebound firing of VL neurons. By inhibiting rebound firing of VL neurons, Parkinson's disease can be treated or prevented.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: December 1, 2020
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Daesoo Kim, Jeongjin Kim, Youngsoo Kim, Minju Jeong
  • Patent number: 10842886
    Abstract: The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 24, 2020
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Jerry R. Mendell, Brian K. Kaspar, Samiah Al-Zaidy
  • Patent number: 10842853
    Abstract: Codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells are provided, including sequences with high nucleotide sequence identity to the CS02, CS03, CS04, CS05, and CS06 sequences. Mammalian gene therapy vectors, such as adeno-associated viral vectors, and methods for treating hemophilia B using those vectors are also provided.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 24, 2020
    Assignees: Baxalta Incorporated
    Inventors: Franziska Horling, Johannes Lengler, Falko-Gunter Falkner, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Patent number: 10828346
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: November 10, 2020
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Patent number: 10793835
    Abstract: The invention provides an isolated chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated viral (AAV) genome, an isolated rBoV comprising human bocavirus capsid protein and a recombinant BoV genome, and uses therefor. For example, the chimeric virus may be employed to deliver transgenes, such as those encoding therapeutic or prophylactic gene products, to mammalian cells.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: October 6, 2020
    Assignees: University of Iowa Research Foundation, University of Kansas
    Inventors: Ziying Yan, John F. Engelhardt, Jianming Qiu